Summary
Thirty-two patients with advanced cancer were treated in a phase I–II trial with ifosfamide plus mesnum. At doses up to 300 mg ifosfamide/kg the administration of mesnum prevented most of the expected kidney and bladder toxicity. With this high dose range hemopoietic dose-limiting. Only one of twelve evaluable patients with breast cancer showed definite therapeutic benefit. Complete remission or partial remission was seen in three patients with non-Hodgkin lymphoma and one patient with Hodgkin's disease.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ahmann DL, Bisel HF, Hahn RG (1974) Phase II clinical trial of ifosfamide (NSC-109724) in patients with advanced breast cancer. Cancer Chemother Rep 58:861–865
Brock N (1980) The development of mesnum for the inhibition of uro-toxic side effects of cyclophosphamide, ifosfamide and other oxazaphosphorine cytostatics. Recent Results Cancer Res 74:270–728
Brock N, Stekar J, Pohl J, Niemeyer U, Scheffler G (1979a) Acrolein, the causative factor of urotoxic side effects of cyclophosphamine, ifosfamide, trofosfamide and sufosfamide. Arzneim Forsch 29:659–661
Brock N, Stekar J, Pohl J (1979b) Antidot gegen urotoxische Wirkugen der Oxazaphosphorin-Derivate Cyclophosphamid, Ifosfamid und Trofosfamid. Naturwissenschaften 66:60–61
Bryant BM, Jarman M, Ford HT, Smith IE (1980) Prvention of isophosphamide-induced urothelial toxicity with 2-mercaptoethane sulfonate sodium (Mesnum) in patients with advanced carcinoma. Lancet II:257–259
Buzdar AU, Legha SS, Tashima CK, Yap HY, Hortobagy GN, Hersh EM, Blumenschein GR, Bodey GP (1979) Ifosfamide versus cyclophosphamide in combination drug therapy for metastatic breast cancer. Cancer Treat Rep 63:115–120
Cabanillas F, Hagemeister F, Bodey GP, Freireich EJ (1981) Ifosfamide, methotrexate, VP-16 (IMVP-16), an effective salvage regimen for lymphoma. Proc AACR/ASCO 22:517
Costanzi JJ, Gagliano R, Loukas D, Panettieree FJ, Hokanson JA (1978) Ifosfamide in the treatment of recurrent or disseminated lung cancer. Cancer 41:1715–1719
Creaven PJ, Allen LM, Cohen MH, Nelson RL (1976) Studies on the clinical pharmacology and toxicology of isophosphamide (NSC 109724). Cancer Treat Rep 60:445–449
Falkson G (1977) Clinical experience with ifosfamide at various ranges and in combination with VP 16-213. International Holoxan Symposium Düsseldorf 1977, pp 168–170
Falkson G, Falkson HC (1976) Further experience with ifosfamide. Cancer Treat Rep 60:955–957
Fossa SD, Talle K (1980) Treatment of metastatic renal cancer with ifosfamide and mesnum with and without irradiation. Cancer Treat Rep 64:1103–1108
Gad-er-Mawla N, Ziegler JL (1981) Ifosfamide treatment of pancreatic cancer. Cancer Treat Rep 65:357–358
Papermaster-Bender G, Laufman LR, File S, Guy JT (1980)cis-Platinum and ifosfamide in refractory lung cancer. Proc AACR/ASCO 21:451
Scheef W, Klein HO, Brock W, Burkert H, Günther U, Hoefer-Janker H, Schnitker J, Voigtmann R (1979) Controlled clinical studies with an antidote against the uro-toxicity of oxazaphosphorines: a preliminary study. Cancer Treat Rep 63:501–505
Van Dyk JJ, Falkson HC, van der Merwe AM, Falkson G (1972) Unexpected toxicity in patients treated with ifosfamide. Cancer Res 32:921–924
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Falkson, G., Van Dyk, J.J., Stapelberg, R. et al. Mesnum as a protector against kidney and bladder toxicity with high-dose ifosfamide treatment. Cancer Chemother. Pharmacol. 9, 81–84 (1982). https://doi.org/10.1007/BF00265383
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00265383